Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab vs Omalizumab in Allergen-Induced Asthma
NCT01703312Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ligelizumab in allergic asthma, sponsored by Novartis. Started Nov 2012; status: completed.
02
Drugs
ligelizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01703312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703312.